For four decades, the two-hit hypothesis stood as a pillar of cancer biology. If you inherited one broken copy of a tumor suppressor gene, the thinking went, you still had a backup. Only a second random mutation — a second hit — would flip the switch to malignancy. That framework is now under serious pressure.
A study published May 9, 2024, by scientists in Singapore and the United Kingdom has cracked open a different door. It shows that a single mutated copy of the BRCA2 gene, long associated with breast and ovarian cancer, can become dangerously active when the body’s metabolism is thrown off by a poor diet or unmanaged diabetes. The second hit may not be a genetic mutation at all. It may be a chemical byproduct of how the body processes sugar.
This changes the calculus for millions of people walking around with one faulty copy of BRCA2. For years, they were told their risk was elevated but not inevitable — a probabilistic warning. The new work suggests that risk is conditional on metabolic environment.
Lead author Li Ren Kong, a cancer pharmacologist at the Cancer Science Institute of Singapore, said the study reveals that mutations in just one copy of the BRCA2 gene can significantly increase susceptibility to cancer when the body is exposed to environmental stresses. The environment here is not air or water. It is the chemical landscape inside the cell, shaped by what we eat.
The researchers used mouse models, human tissue samples, and breast organoids grown in the lab. They tracked how shifts in glucose metabolism temporarily disable genes that normally suppress tumors. A specific byproduct of sugar processing was identified as the agent that knocks out the backup copy of the tumor suppressor gene. Not permanently. Not through mutation. Through a chemical interference that can be reversed.
That reversibility is the part that demands attention. If the second hit is not a permanent scar on the DNA but a metabolic state, then changing that state could change the outcome. It opens a line of questioning that runs directly into daily life: what happens to cancer risk when a person with a single BRCA2 mutation eats a high-sugar diet for years? What happens when diabetes goes untreated and glucose metabolism runs wild?
The study does not answer those questions definitively. It establishes a mechanism. The mechanism says that metabolic stress — the kind driven by unhealthy eating and unmanaged metabolic disease — can create a chemical environment where one bad copy of a tumor suppressor gene is enough to push a cell toward cancer.
That is a different kind of warning than the one the medical community has been issuing. It is more specific. It ties a genetic vulnerability directly to a modifiable behavior. It also raises the stakes for managing conditions like diabetes, which have long been linked to cancer risk through statistical association but without a clear biological bridge. This study supplies that bridge.
The next steps are obvious but difficult. Clinical studies will need to track whether aggressive metabolic management — tight glucose control, dietary intervention — actually reduces cancer incidence in people with BRCA2 mutations. Mouse models and organoids can show mechanism. They cannot show population-level outcomes.
For now, the practical consequence is a shift in how doctors might counsel patients. The old message was: you have a genetic risk, get screened. The new message, if this work holds up, may be: you have a genetic risk, and what you eat may determine whether it ever matters.
